QUICK ANSWER
Coverage Overview
Short answer: Yes, if your Aetna plan includes weight-loss drug coverage. Since July 2025, Wegovy has been a preferred GLP-1 medication on CVS Caremark formularies (Aetna's pharmacy benefit manager), but many employer plans leave weight-loss drugs out. Per KFF, GLP-1s for weight loss were covered by 43% of firms with 5,000+ workers, and 16% of firms with 200–999 workers (2025). Where it's covered, you'll need prior authorization.
Is Wegovy covered by Aetna?
Yes, if your plan covers weight-loss drugs. Wegovy is a preferred weight loss medication on Aetna's standard formularies:
- Wegovy became the preferred GLP-1 on CVS Caremark/Aetna formularies in July 2025
- Prior authorization is required — you'll need to meet BMI and documentation criteria
- If your PA is denied, 65%+ of appeals succeed with proper documentation[5]
Who this guide is for
Aetna members seeking Wegovy coverage through employer-sponsored commercial plans, individual/ACA marketplace plans, or Aetna Medicare Advantage.
Good News: Wegovy Is Preferred
CVS Caremark (Aetna's pharmacy benefit manager) made Wegovy their preferred GLP-1 in July 2025 after negotiating a deal with Novo Nordisk. This means Aetna plans that include weight-loss drug coverage can cover Wegovy, with prior authorization.
- From July 1, 2025 to September 30, 2026, Zepbound was nonpreferred or excluded on CVS Caremark’s most common commercial formularies, with Wegovy preferred (not every one of those formularies excluded Zepbound); Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize)
- Prior authorization is still required—see PA requirements below
- Some self-funded employer plans may have different formularies
To confirm your specific coverage, call Aetna using our script.
What to Know About Prior Authorization
Even though Wegovy is covered, prior authorization (PA) can still be denied if you don't meet all the criteria. Common denial reasons include insufficient BMI documentation, missing records of the required weight-management program, or a plan-specific step-therapy rule.
- 65%+ of appealed denials are overturned when properly documented[5]
Preparing for PA? See exactly what Aetna requires →
Coverage Outlook for 2026
Wegovy remains a preferred GLP-1 on Aetna/CVS Caremark plans. Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize). For Medicare Advantage members, the Medicare GLP-1 Bridge covers Wegovy for weight loss ($50 per monthly fill, with conditions).
Why this matters: Wegovy is the first weight-loss medication approved to reduce cardiovascular risk (FDA, March 8, 2024, Wegovy injection), for heart attack and stroke prevention in adults with established cardiovascular disease and either obesity or overweight. If that describes you, the CV indication can support a coverage request.
Last updated October 6, 2026 · Key facts verified October 5, 2026 · Full page reviewed October 5, 2026
Aetna's Key Coverage Factor: CVS Caremark
Unlike insurers with regional variation, Aetna coverage is primarily controlled by one factor: CVS Caremark, their pharmacy benefit manager (PBM).
Getting Wegovy approved depends on two things:
- Meeting PA Requirements — BMI criteria, documented lifestyle efforts, possible step therapy
- Your Plan Type — some self-funded employers may have different formularies
Since Wegovy is a preferred GLP-1, focus on meeting PA requirements. See PA requirements →
Pro tip: Have your doctor document your BMI, comorbidities, and lifestyle efforts before submitting the PA.
Things to Keep in Mind
- Wegovy is preferred on CVS Caremark's commercial template formularies — CVS Caremark made it their primary GLP-1 in July 2025; whether your plan covers weight-loss drugs at all is up to your employer or plan
- Prior authorization is required — you'll need to meet BMI and documentation criteria
- If denied, file an appeal — 65%+ of appealed denials are overturned when properly documented[5]
- Cardiovascular indication may help your case — Wegovy is FDA-approved to reduce heart attack/stroke risk in adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets))
If your PA is denied, don't give up — you can appeal with the right documentation.
Ready to get approved? Understanding what Aetna requires makes approval much more likely.
See PA requirements →WHY WEGOVY IS PREFERREDThe CVS Caremark Connection
The CVS Caremark Connection
Understanding why Wegovy is Aetna's preferred GLP-1 helps explain your coverage options.
CVS Health Owns Both Aetna and CVS Caremark
CVS Health acquired Aetna in 2018, and CVS Caremark manages pharmacy benefits for many Aetna plans. In July 2025, CVS Caremark made Wegovy their preferred GLP-1 medication after negotiating a deal with Novo Nordisk.[1][2]
Why CVS Caremark Chose Wegovy
- Novo Nordisk deal: CVS Caremark negotiated preferred pricing for Wegovy, making it their primary GLP-1 option
- Zepbound restricted, then restored: from July 2025, Eli Lilly's Zepbound was nonpreferred or excluded on some (the most common) CVS Caremark commercial template formularies, not all; Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize)
- Cardiovascular benefit: Wegovy is the first weight-loss medication approved to reduce cardiovascular risk (FDA, March 8, 2024, Wegovy injection) (in adults with established cardiovascular disease and either obesity or overweight)
What This Means for Aetna Members
- Standard Aetna plans: Wegovy is covered with prior authorization, if the plan includes weight-loss drug coverage
- Self-funded employer plans: May have different formularies—check with HR
- Medicare Advantage: The plan's basic Part D coverage excludes drugs used for weight loss, but the Medicare GLP-1 Bridge (outside Part D) covers Wegovy for $50 per monthly fill (with conditions)—see Medicare guide
For more details on how CVS Caremark affects GLP-1 coverage across all insurers: Complete CVS Caremark Guide →
Now that you understand why Wegovy is preferred, here's what you need for prior authorization approval.
See PA requirements →COVERAGE BY PLAN TYPEHow Plan Type Affects Coverage
How Plan Type Affects Coverage
Your Aetna Wegovy coverage depends on your plan type:
- Commercial plans with weight-loss coverage: Wegovy is covered with prior authorization (preferred GLP-1)
- Self-funded employers: May have different formularies—check with HR
- Medicare/Medicaid: Medicare covers Wegovy for weight loss only through the Medicare GLP-1 Bridge, with conditions; Medicaid varies by state—see specific guides
Good News for Aetna Members With Weight-Loss Coverage
Since July 2025, Wegovy is a preferred GLP-1 medication on CVS Caremark's commercial template formularies. Aetna commercial plans that include weight-loss drug coverage can cover it with prior authorization.
The main question is whether you meet the PA requirements—see requirements below.
Aetna Plan Types and Coverage Status
| Your Plan Type | Coverage Status | Key Details |
|---|---|---|
| Standard Plan | Covered (w/PA) | Wegovy is preferred GLP-1 if the plan covers weight-loss drugs; requires prior authorization[1] |
| Advanced Control Plan | Covered (w/PA) | Same as standard if the plan covers weight-loss drugs; PA requirements apply[2] |
| Self-Funded Employer | Varies | Employers can customize formularies; check with HR |
| ACA Marketplace | Varies | Depends on the plan and state; check the plan's formulary. PA required where covered |
| Medicare Advantage | Bridge: $50 per monthly fill (with conditions) | Basic Part D coverage excludes drugs used for weight loss; the Medicare GLP-1 Bridge is separate (outside Part D, with conditions). See Medicare guide[3] |
| Aetna Medicaid | Varies by state | Follows your state's Medicaid rules (13 states (as of January 2026) covered GLP-1s for obesity); see Medicaid guide[4] |
Status key: Covered = on formulary with PA Varies = depends on employer Limited = restricted coverage
More Details by Plan Type
Standard/Advanced Control Plans — Covered with PA
If you have a standard Aetna commercial plan that covers weight-loss drugs, Wegovy is a preferred GLP-1 medication on CVS Caremark's commercial template formulary (prior authorization applies).
- BMI ≥30 (or ≥27 with comorbidities)
- At least 6 months in a documented weight-management program
- No other weight-loss drug required first on Aetna's standard policy (some employer plans add a step)
Self-Funded Employer Plans — Check with HR
Many large companies pay for healthcare themselves (this is called "self-funded"). Aetna just handles the paperwork.
That means your employer — not Aetna or CVS Caremark — decides the exact formulary.
ACA Marketplace Plans — Check Your Plan
If you bought your plan through Healthcare.gov or directly from Aetna, whether it covers weight-loss drugs depends on the plan and your state.
- Confirm Wegovy is on your specific plan's formulary
- Meet PA requirements (BMI, lifestyle documentation)
- Work with your doctor to submit the PA
Aetna Medicare Advantage — Through the Medicare GLP-1 Bridge
By law, basic Part D coverage (including your Medicare Advantage plan's drug coverage) excludes drugs used for weight loss, but the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027), which runs outside the Part D benefit, covers it for $50 per monthly fill, with conditions. Your plan may also cover Wegovy for cardiovascular risk reduction, subject to its formulary, prior authorization and exceptions process.
- The Medicare GLP-1 Bridge for weight loss (Part D plans and pharmacies don’t opt in, and you don’t enroll separately; your prescriber must get prior authorization)
- Cardiovascular risk reduction indication for adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets))
- Self-pay options like NovoCare ($349/month ($399 for Wegovy HD 7.2 mg); If you have government insurance, ask NovoCare whether you can use self-pay pricing)
Ready to get approved? Here's exactly what Aetna requires for prior authorization.
See PA requirements →YOUR NEXT STEPSBased on Your Situation
Based on Your Situation
Choose the path that matches your current situation:
Starting Fresh?
Haven't applied yet or want to prepare for the best chance of approval.
- Review PA requirements before your doctor submits
- Use our call script to confirm coverage
PA Denied?
Your prior authorization was rejected. Don't give up—you can appeal.
- 65%+ of appeals succeed with proper documentation
- For ACA-regulated and employer (ERISA) plans you have 180 days to file an appeal (check your denial letter)
Self-Funded Plan Doesn't Cover It?
Your employer's self-funded plan has a different formulary that excludes Wegovy.
- Request a formulary exception
- Explore self-pay options ($349/month ($399 for Wegovy HD 7.2 mg) with NovoCare)
If Your PA Was Denied — Check your denial letter.
- "Not medically necessary" or "step therapy required" = PA denial (you can appeal)
- "Excluded benefit" or "not covered" = your plan's formulary differs from standard (request exception)
WHAT'S COMING
Aetna Coverage Outlook for 2026
Wegovy Coverage Expected to Continue in 2026
CVS Caremark's deal with Novo Nordisk positions Wegovy as a preferred GLP-1 option for Aetna plans. Where an Aetna commercial plan covers weight-loss drugs, Wegovy remains a preferred option in 2026, subject to prior authorization.
What to Watch For
Standard Commercial Plans
Wegovy's preferred status from July 2025 continues. Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize).
- Wegovy remains a preferred GLP-1 for weight loss, alongside Zepbound
- The cardiovascular indication (adults with established cardiovascular disease and either obesity or overweight) can support a coverage request
Self-Funded Employer Plans
Self-funded employers have flexibility to follow or customize the CVS Caremark formulary.
- Some follow the standard CVS Caremark formulary; others exclude weight-loss drugs
- Some may have different PA requirements
- Check with HR during open enrollment for any changes
Medicare/Medicaid Policy Changes
The Medicare GLP-1 Bridge is live (July 1, 2026 – December 31, 2027) and covers Wegovy for weight loss for $50 per monthly fill, with conditions. See our Medicare coverage guide for the latest updates.
- By law, basic Part D coverage still excludes weight-loss drugs (the Bridge runs outside Part D)
- BALANCE Model (Part D): Delayed, with no new start date
- Medicaid coverage remains state-dependent
What This Means for You
- Preferred status continues: Wegovy remains preferred on CVS Caremark's commercial template formularies, alongside Zepbound
- Focus on PA requirements: Meeting criteria is key to approval
- Cardiovascular indication: if you have established cardiovascular disease and either obesity or overweight, Wegovy's CV approval (injection: March 8, 2024 (Wegovy injection)) can support your case
- During open enrollment: Confirm no changes to your specific plan's requirements
CALL YOUR INSURANCEVerify Your Specific Coverage
Verify Your Specific Coverage
Even though it takes a little more time, we recommend calling so you can speak with a person who may have more information than the online directory or PDF formulary listing.
Call Script for Aetna
"Hi, I'm calling to check coverage for a prescription medication. My member ID is [NUMBER]. I need to know:
- Is Wegovy (semaglutide) currently covered on my plan's formulary for weight management?
- If not, is there an exception process I can request?
- What alternative GLP-1 medications ARE covered on my plan?
- If covered, what tier is it on and what are the prior authorization requirements?
- Can you send me the coverage policy in writing?"
Pro tip: Always request coverage criteria in writing. Verbal confirmations aren't binding, and having documentation helps if you need to appeal later.
Check Your Coverage Online
You can also look up Wegovy coverage on Aetna's website:
- Log in to your Aetna member account
- Go to "Find a Medication" or "Drug Lookup"
- Search for "Wegovy" or "semaglutide"
- Review your plan's coverage status and any requirements
Have a Self-Funded Employer Plan? Talk to HR
If your employer self-funds their health plan (common at large companies), they—not Aetna—decide what's covered. Here's how to advocate for Wegovy coverage:
- Ask HR: "Does our plan cover GLP-1 medications for weight management? If not, who decides our formulary?"
- Make the case: Explain how treatment could help with weight-related conditions (diabetes risk, heart disease, joint problems)
- Gather support: If coworkers also want coverage, a group request carries more weight
- Time it right: Ask HR when next year's benefits are decided
- Be patient: Plan changes may not take effect until the next plan year
WHAT AETNA REQUIRESPrior Authorization Requirements
Prior Authorization Requirements
Wegovy Is Covered — PA Is Required
If your Aetna plan covers weight-loss drugs, Wegovy is preferred, so the main hurdle is meeting the prior authorization requirements. Here's what Aetna's published policy requires.[7]
Aetna publishes its Wegovy criteria (written with CVS Caremark) in policy 4774-C.[9] To get Wegovy approved, you must meet all of:
- A 6-month weight-management program first — documented behavioral modification, reduced-calorie diet, and increased physical activity with continuing follow-up (this is the real hurdle, not another drug)
- BMI ≥30, or ≥27 with a weight-related condition (hypertension, type 2 diabetes, or dyslipidemia). Some Aetna plans use a stricter version of the policy that requires BMI ≥35 (plans using policy 6450-C).
- Age 18+ (ages 12–17: BMI at or above the 95th percentile for age and sex, plus the same program)
- No drug step therapy: CVS Caremark's standard Wegovy policy does not require trying and failing another weight-loss drug first (some individual employer plans add it — check yours)
Wegovy also has a separate coverage pathway for cardiovascular risk reduction (established cardiovascular disease + BMI ≥27, if you don't have type 2 diabetes). Newer versions of Aetna's policy also have a MASH (liver disease) pathway for the injection; check your plan's current criteria.
Renewal Requirement — Don't Miss This
Your initial approval runs 7 months (policy 4774-C) or 8 months (2026 policy 6450-C). To renew, the policy requires at least 3 months at a stable maintenance dose and proof you've lost ≥5% of your starting body weight (or kept off your initial 5%); renewals then run 12 months. There's also a quantity limit of one 4-pen box per 28-day fill. If you don't meet the weight-loss threshold, your renewal may be denied.
For complete documentation checklists and PA preparation: Wegovy Prior Authorization Guide →
YOUR PLAN COVERS ITIf Your PA Was Denied
If Your PA Was Denied
Your plan covers Wegovy, but the prior authorization was rejected. This is actually good news — 65%+ of appeals succeed when properly documented.[5]
Common PA Denial Reasons
- Medical necessity not met → Medical Necessity Guide
- Step therapy required → Step Therapy Guide
- BMI criteria not met → BMI Criteria Guide
- Missing lifestyle documentation → Lifestyle Documentation Guide
Aetna Appeal Basics
- Deadline: 180 days for ACA-regulated and employer (ERISA) plans, from the denial to file an internal appeal (your denial letter states your plan's deadline)
- Pharmacy Help Line: 1-888-792-3862 (or the pharmacy number on your member ID card)
- Tip: Ask your doctor for a peer-to-peer review with Aetna's medical director
For complete appeal strategies: Wegovy Appeals Guide → | External Review Process
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get startedFOR SELF-FUNDED PLANS WITH DIFFERENT FORMULARIESIf Your Plan Excludes Wegovy
If Your Plan Excludes Wegovy
Some self-funded employer plans have customized formularies that may not include Wegovy. If your plan excludes it, standard appeals won't work for a plan exclusion, but you have other options.
Your Options
- Request a formulary exception — your doctor can argue medical necessity → What to do if Wegovy is not covered
- Cardiovascular risk reduction — if you have established cardiovascular disease (such as a prior heart attack or stroke) and either obesity or overweight, Wegovy's FDA-approved CV indication (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets)) may support coverage
- Consider Zepbound — if your plan excludes only Wegovy (not all weight-loss drugs): since October 1, 2026 it is an "additional preferred option" alongside Wegovy on CVS Caremark's commercial template formularies (plan sponsors can customize)[10] → Zepbound coverage on Aetna
- Switch plans during open enrollment — if your employer offers multiple options, check for GLP-1 coverage
- Explore self-pay options — NovoCare ($349/month ($399 for Wegovy HD 7.2 mg)) and the Wegovy pill's lower self-pay prices (savings options) may help → Wegovy Cost Guide
About Wegovy's FDA Approvals
Important: Sleep Apnea Coverage Goes to Zepbound, Not Wegovy
Note: Zepbound (tirzepatide), not Wegovy, was FDA-approved to treat obstructive sleep apnea (OSA) in adults with obesity on December 20, 2024.[6] Wegovy does not have FDA approval for sleep apnea.
If you have sleep apnea and want GLP-1 coverage through the OSA indication, ask your doctor about Zepbound instead. Some insurers cover Zepbound for OSA even when they exclude weight loss medications.
For cardiovascular risk reduction, Wegovy may still be an option—it is FDA-approved to reduce heart attack and stroke risk in adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets)).
AETNA WEGOVY COVERAGE
Frequently Asked Questions
Yes, if your Aetna plan includes weight-loss drug coverage. Since July 2025, Wegovy has been a preferred GLP-1 medication on CVS Caremark formularies (Aetna's pharmacy benefit manager), but whether weight-loss drugs are covered at all depends on your employer or plan. Where it's covered, you'll need prior authorization; Aetna's standard policy requires BMI ≥30 (or ≥27 with comorbidities; ≥35 on some plans) and at least 6 months in a documented weight-management program. Aetna's standard policy doesn't require trying another weight-loss drug first. Check with HR to confirm your plan covers weight-loss drugs.
CVS Caremark negotiated a deal with Novo Nordisk (Wegovy's manufacturer) that made Wegovy the preferred GLP-1 medication starting July 2025. From July 1, 2025 to September 30, 2026, Zepbound was nonpreferred or excluded on some (the most common) CVS Caremark commercial template formularies, not all; since October 1, 2026, Zepbound is back on those template formularies as an additional preferred option alongside Wegovy (plan sponsors can customize). Wegovy also has an FDA approval for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection)). Wegovy has a list price of $1,349/month (see our cost guide for savings options).
To get Wegovy approved on Aetna under its standard policy, you'll need: BMI of 30 or higher, or BMI of 27+ with a health condition like high blood pressure, type 2 diabetes, high cholesterol, or sleep apnea. You'll also need at least 6 months in a documented weight-management program (diet, exercise and behavior change). Aetna's standard policy doesn't require trying another weight-loss drug first, but some employer plans add a step, and some plans require BMI ≥35. Requirements vary by plan—always ask for your plan's specific criteria in writing.
If your PA is denied, don't give up—65%+ of appeals succeed with proper documentation. For ACA-regulated and employer (ERISA) plans you have 180 days to file an appeal (your denial letter states the exact deadline). Submit an appeal with: a letter from your doctor explaining medical necessity, documentation of any comorbidities, and evidence of why you need Wegovy specifically. Ask your doctor for a peer-to-peer review with Aetna's medical director. If the internal appeal fails, you can request an external review within 4 months (at least; check your state)—these succeed 40-50% of the time.
It depends on your employer's specific formulary. Self-funded employers decide whether to cover weight-loss drugs at all, and can customize CVS Caremark's formulary. Ask HR: "Is our health plan self-funded?" and "Does our plan cover Wegovy for weight management?" Your employer controls the formulary, not Aetna.
No, Wegovy does not have FDA approval for sleep apnea. It was Zepbound (tirzepatide) that received FDA approval for obstructive sleep apnea (OSA) in adults with obesity on December 20, 2024—the first medication ever approved for this condition. If you have sleep apnea and want GLP-1 coverage through the OSA pathway, ask your doctor about Zepbound instead. Wegovy's additional FDA approval is for cardiovascular risk reduction (reducing heart attack and stroke risk) in adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets)).
Aetna doesn't publish a typical turnaround for Wegovy. For employer plans, federal rules allow up to 15 days for a standard prior authorization decision (one 15-day extension allowed) and 72 hours for an urgent one if your doctor indicates medical urgency. To speed up the process, make sure your doctor includes all required documentation upfront: BMI measurements, comorbidity diagnoses, and lifestyle modification records. Call Aetna's pharmacy line at 1-888-792-3862 (or the number on your card) to check status.
YOUR PATH FORWARD
What's Next
Wegovy Coverage: Other Major Insurers
See how other insurers compare on Wegovy coverage:
- UnitedHealthcare — Coverage varies by plan; many require PA
- Blue Cross Blue Shield — Major 2026 coverage restrictions announced
- Cigna — Cigna plans may require step therapy; check your plan’s policy
- Anthem Blue Cross — Separate policies from other BCBS affiliates
- Kaiser Permanente — Regional variations
Other GLP-1 Medications at Aetna
Aetna's coverage varies by medication. Compare your options:
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get startedAppeal outcomes are not guaranteed and depend on your specific plan and documentation.
References
- CVS Health. (June 27, 2025). "Improving access and affordability to high-cost weight management drugs." CVS Caremark prefers Wegovy on its commercial template formularies from July 1, 2025. cvshealth.com
- Aetna. (2026). "Weight Loss (BMI 35) GIP/GLP-1, GLP-1 Agonists PA with Limit, policy 6450-C." Stricter criteria some Aetna plans use. aetna.com
- Centers for Medicare & Medicaid Services. (2024). "Medicare Prescription Drug Benefit Manual, Chapter 6." Part D exclusions. https://www.cms.gov/medicare/prescription-drug-coverage/prescriptiondrugcovcontra/partdmanuals
- KFF. (2024). "Medicaid Coverage of GLP-1 Weight Loss Drugs." https://www.kff.org/medicaid/issue-brief/medicaid-coverage-of-glp-1-weight-loss-drugs/
- American Medical Association / KFF Analysis. (2024). "Over 80% of Prior Auth Appeals Succeed—Why Aren't There More?" https://www.ama-assn.org/practice-management/prior-authorization/over-80-prior-auth-appeals-succeed-why-aren-t-there-more
- FDA. (2024). "FDA Approves First Medication for Obstructive Sleep Apnea." https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
- Novo Nordisk. (2025). "Wegovy Prior Authorization Resource Guide." https://www.wegovy.com/assets/pdf/wegovy_Prior_Authorization_Resource_Guide.pdf
- Honest Care. (2025). "GLP-1 Patient Access Report — Q3/Q4 2025." https://www.findhonestcare.com/insights/glp1-coverage-2025/
- Aetna / CVS Caremark. "Wegovy PA with Limit, policy 4774-C (P08-2024)." aetna.com
- CVS Health. (2026). "CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications with Expanded Coverage Options." Announced May 28, 2026: Zepbound returns to standard commercial formularies as an additional preferred option effective October 1, 2026; Wegovy keeps its preferred status. https://www.cvshealth.com/news/company-news/cvs-caremark-delivers-affordability-and-access-to-glp-1-weight-management-medications-with-expanded-coverage-options.html
Last updated October 6, 2026 · Key facts verified October 5, 2026 · Full page reviewed October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.